ストックスクリーナーアプリを入手
6.50
4.00%
0.25
Fennec Pharmaceuticals Inc (FENC) 最新ニュース
(FRX) Trading Report (FRX:CA) - Stock Traders Daily
Treasury Yields: Can Fennec Pharmaceuticals Inc stock outperform in a bear market2026 Reactions & Verified Entry Point Detection - baoquankhu1.vn
US Market Recap: What is the long term forecast for Fennec Pharmaceuticals Inc stock2026 Key Lessons & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Stock Recap: Can Fennec Pharmaceuticals Inc expand its profit marginsGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
FRX.CA Forecast, Price Target & Analyst Ratings | FENNEC PHARMACEUTICALS INC (TSX:FRX) - ChartMill
Aug Spikes: Why is Fennec Pharmaceuticals Inc stock going down2026 Macro Impact & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC) - The Globe and Mail
H.C. Wainwright reiterates Fennec Pharmaceuticals stock rating on expanded study - Investing.com
Fennec Pharmaceuticals Announces New Investigator-Sponsored Study of PEDMARK® for Preventing Cisplatin-Induced Hearing Loss in AYA and Adult Cancer Patients - Minichart
Fennec Pharmaceuticals Inc. (FENC) stock price, news, quote and history - Yahoo Finance UK
Fennec Pharmaceuticals: University of Arizona launches PEDMARK study in AYA and adult cisplatin patients - TradingView — Track All Markets
Fennec (FENC) backs new University of Arizona study on PEDMARK use in cisplatin-treated patients - Stock Titan
Fennec Pharmaceuticals Inc. Announces Investigator-Sponsored Study of PEDMARK in AYA and Adult Patients With Solid Tumors Receiving Cisplatin - marketscreener.com
Fennec Pharmaceuticals urges focus on community and science to shape a healthier world - Traders Union
Fennec Pharmaceuticals: University Of Arizona Cancer Center Investigator-Sponsored Study Advances PEDMARK In AYA And Adult Cancer Patients - Pulse 2.0
FENC Technical Analysis & Stock Price Forecast - Intellectia AI
Fennec Backs New PEDMARK Study Expanding Cisplatin Ototoxicity Research to Adult Cancers - TipRanks
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center - Bitget
Can a hearing-loss drug help more adults on cisplatin? Arizona study starts - Stock Titan
Trend Recap: Can Fennec Pharmaceuticals Inc sustain earnings growth2026 Short Interest & Step-by-Step Swing Trade Plans - baoquankhu1.vn
(FENC) Risk Channels and Responsive Allocation - Stock Traders Daily
FENC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Adherex Technologies (NASDAQ:FENC) Cut to Hold at Wall Street Zen - MarketBeat
Adherex Technologies (NASDAQ:FENC) Director Rosty Raykov Sells 10,946 Shares - MarketBeat
[Form 4] FENNEC PHARMACEUTICALS INC. Insider Trading Activity - Stock Titan
Fennec (FENC) CEO gets 200,000 options and new common shares - Stock Titan
FENNEC (FENC) director exercises 15,598 options and sells shares under 10b5-1 plan - Stock Titan
CMO at Fennec (NASDAQ: FENC) receives 120,000 stock options award - Stock Titan
Fennec (NASDAQ: FENC) CCO gets 120,000 options, 20,679 shares - Stock Titan
Public market insider net buying at Fennec Pharmaceuticals (FRX) - The Globe and Mail
FENC (NASDAQ) insider sale notice: 10,946 shares via option exercise - Stock Titan
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
HC Wainwright Has Bearish Forecast for FENC Q1 Earnings - MarketBeat
Equities Analysts Offer Predictions for TSE:FRX Q1 Earnings - MarketBeat
Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Research Analysts Set Expectations for TSE:FRX Q3 Earnings - Defense World
Aug Ideas: Does Fennec Pharmaceuticals Inc have a competitive edge2026 Trade Ideas & Long-Term Growth Plans - baoquankhu1.vn
Fennec Pharmaceuticals earnings are imminent; these most accurate analysts revise forecasts ahead of earnings call - MSN
CEO Moves: Can Fennec Pharmaceuticals Inc expand its profit marginsWeekly Trade Analysis & Risk Controlled Daily Plans - baoquankhu1.vn
HC Wainwright Issues Negative Forecast for FENC Earnings - MarketBeat
24 new Fennec hires get options at $5.77 under Nasdaq rule - Stock Titan
Can Fennec Pharmaceuticals Inc stock double in the next yearStock Surge & Accurate Intraday Trade Tips - baoquankhu1.vn
Income Plays: Does Fennec Pharmaceuticals Inc have a sustainable dividend2026 Fed Impact & High Return Stock Watch Alerts - baoquankhu1.vn
Fennec Pharmaceuticals 2025 Annual Report: PEDMARK® Commercialization, Risks, and Intellectual Property Overview - Minichart
Adherex Technologies (NASDAQ:FENC) Cut to Strong Sell at Zacks Research - Defense World
Fennec Posts Record PEDMARK Sales in 2025 as Clinical and Commercial Momentum Builds - TipRanks
Fennec Pharmaceuticals 2025 10-K: Revenue $44.6M, Net Loss $(9.7)M - TradingView
Fennec (NASDAQ: FENC) expands PEDMARK reach and delays generic entry - stocktitan.net
Adherex Technologies (NASDAQ:FENC) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Fennec Pharmaceuticals (TSE:FRX) Stock Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat
Fennec (NASDAQ: FENC) CFO exercises 13,072 stock options in Form 4 - Stock Titan
Fennec (NASDAQ: FENC) Chief Strategy Officer exercises options, holds 145,300 shares - Stock Titan
Fennec Pharmaceuticals (FENC) Quarterly Loss Near Breakeven Challenges Bearish Profitability Narratives - Sahm
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2025 Earnings Call Transcript - Insider Monkey
Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Can Afford To Invest In Growth - Yahoo Finance
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):